Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer

Wang, Shujie; Liu, Wenjing; Ni, Yueli; Wang, Lifeng; Zhu, Yuzhi; Shi, Qiong; Yi, Zihan; Wang, Wenjie; Liu, Lili; Yang, Lijuan; Kuang, Yingmin; Zhu, Yuechun; Zhang, Qiao; Yang, Zhe

doi:10.7150/jca.54576



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(9):2550-2559. doi:10.7150/jca.54576 This issue Cite

Research Paper

Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer

Shujie Wang^1*, Wenjing Liu^1*, Yueli Ni², Lifeng Wang², Yuzhi Zhu², Qiong Shi³, Zihan Yi⁴, Wenjie Wang², Lili Liu¹, Lijuan Yang², Yingmin Kuang⁵, Yuechun Zhu^2✉, Qiao Zhang^2✉, Zhe Yang^1✉

1. Department of pathology, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.
2. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, Yunnan, China.
3. Department of Clinical Laboratory, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Yunnan, China.
4. Department of Medical Oncology, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Yunnan, China.
5. Department of Organ Transplantation, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.
*These authors contributed equally to this work.

✉ Corresponding authors: Zhe Yang, Professor, Department of pathology, The First Affiliated Hospital of Kunming Medical University, No.295 Xichang Road, Wuhua District, Kunming 650032, Yunnan Province, China. E-mail: zyangpkucom, yangzheedu More

Citation:

Wang S, Liu W, Ni Y, Wang L, Zhu Y, Shi Q, Yi Z, Wang W, Liu L, Yang L, Kuang Y, Zhu Y, Zhang Q, Yang Z. Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. J Cancer 2021; 12(9):2550-2559. doi:10.7150/jca.54576. https://www.jcancer.org/v12p2550.htm

Other styles

Abstract

Pancreatic cancer is associated with poor prognosis due to limited therapeutic options. Excision repair cross-complementing 3 (ERCC3) is an important member of nucleotide excision repair (NER) that is overexpressed in some cancers and may be regarded as a poor prognostic factor. Yet, its role in pancreatic cancer remains unclear. This study aimed to investigate the expression and functions of ERCC3 in pancreatic cancer patients and its relation with clinicopathological features. Our data suggested that the protein expression level of ERCC3 was higher in tumor tissues than in adjacent tissues. In addition, the expression of ERCC3 has shown to be associated with the tumor extent (p=0.035). Besides, analysis of the dataset in The Cancer Genome Atlas (TCGA) revealed that high expression of ERCC3 was associated with poor overall survival in pancreatic cancer patients (p=0.0136). In Cox regression analysis, ERCC3 was an independent prognostic factor for overall survival in pancreatic cancer (p<0.001). Furthermore, our in vitro data further suggested that the overexpression of ERCC3 significantly promoted pancreatic cancer (BxPC-3, CFPAC-1, and PANC-1 cells) proliferation, invasion, and migration. Taken together, this study suggested that high expression of ERCC3 might be a poor prognostic factor in human pancreatic cancer and might be used as a promising therapeutic target for pancreatic cancer treatment.

Keywords: ERCC3, pancreatic cancer, prognosis biomarker, TCGA data mining, immunohistochemistry

Citation styles

APA

Wang, S., Liu, W., Ni, Y., Wang, L., Zhu, Y., Shi, Q., Yi, Z., Wang, W., Liu, L., Yang, L., Kuang, Y., Zhu, Y., Zhang, Q., Yang, Z. (2021). Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. Journal of Cancer, 12(9), 2550-2559. https://doi.org/10.7150/jca.54576.

ACS

Wang, S.; Liu, W.; Ni, Y.; Wang, L.; Zhu, Y.; Shi, Q.; Yi, Z.; Wang, W.; Liu, L.; Yang, L.; Kuang, Y.; Zhu, Y.; Zhang, Q.; Yang, Z. Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. J. Cancer 2021, 12 (9), 2550-2559. DOI: 10.7150/jca.54576.

NLM

CSE

Wang S, Liu W, Ni Y, Wang L, Zhu Y, Shi Q, Yi Z, Wang W, Liu L, Yang L, Kuang Y, Zhu Y, Zhang Q, Yang Z. 2021. Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. J Cancer. 12(9):2550-2559.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.